Preparing a nexus letter? Explore Raven Nexus. Organize selected records for a clinician-review draft or check a letter you already have. Start with a free readiness check; editable clinician-review drafts are available with Standard or Plus. Explore the Nexus letter tool. No clinician or signature is included. Your clinician makes the independent medical judgment, and a separate nexus opinion is not always needed.

Erectile dysfunction secondary to PTSD is one of the most commonly granted secondary claims in the VA system, and one of the most badly handled. The schedular rating under DC 7522 lands at 0% in most cases, and the average veteran reads "got nothing." The 0% grant is supposed to trigger an automatic SMC-K award worth $139.87/month in 2026, tax-free, for life.

The math on a missed SMC-K award over a decade or two gets ugly fast. I pulled the regulatory framework, the medical literature on the two causal pathways, and what the Board has done with these cases at appeal. The pattern is consistent enough that I think this is the single most under-paid corner of the VA rating schedule.

TL;DR

  • ED secondary to PTSD is governed by 38 CFR § 3.310, with both causation and aggravation theories available per Allen v. Brown (7 Vet. App. 439, 1995).
  • The medical literature backs two pathways: PTSD-driven autonomic nervous system dysregulation causing vascular ED, and SSRI / SNRI / benzodiazepine medications causing pharmacological ED.
  • The schedular rating under 38 CFR § 4.115b, DC 7522 is 0% in most cases. The November 2021 amendment to DC 7522 now allows a compensable 20% rating when there's documented penile deformity plus loss of erectile power.
  • The 0% rating is supposed to trigger SMC-K automatically under 38 CFR § 3.350(a). Per the BVA decisions I pulled in my ED research report, that automatic award is missed often.
  • SMC-K is $139.87/month in 2026, tax-free, additive to the base compensation. Over 20 years of a missed award, that's roughly $27,000 to $30,000 in retroactive exposure plus the ongoing monthly payment.
  • In Claim Raven's analysis of 783 ED cases at the BVA, denials run at 84.7 percent and grants at only 7.8 percent. The gap is almost entirely a nexus story: 636 of those cases have "not applicable" nexus quality and grant at 0.3 percent, while the 51 cases with a strong nexus opinion grant at 92.2 percent.

The Regulatory Frame: 38 CFR § 3.310 and the Two Theories That Work

Secondary service connection lives at 38 CFR § 3.310. The regulation does two distinct things, and both matter for ED secondary to PTSD.

Causation under § 3.310

First, it allows service connection for a disability that's "proximately due to or the result of a service-connected disease or injury." That's straight causation. The veteran has to show PTSD caused the ED.

Aggravation under Allen v. Brown

Second, since the Court's decision in Allen v. Brown (7 Vet. App. 439, 1995), the regulation also recognizes aggravation. If a veteran had ED that was made worse by service-connected PTSD or by medications prescribed for PTSD, that's a separate, independent theory of entitlement. The veteran can win on either.

For ED specifically, the aggravation theory carries weight that I don't think gets fully appreciated. A lot of veterans had some baseline level of erectile difficulty before PTSD really took hold, or before they started on SSRIs. The regulation doesn't require them to prove the entire ED is service-connected. It just requires them to show PTSD or PTSD medications made the existing condition worse than its natural progression. That's a much easier evidentiary lift.

Pathway One: Autonomic Nervous System Dysregulation and Vascular ED

PTSD does measurable things to the autonomic nervous system. The sympathetic "fight or flight" half runs chronically elevated. The parasympathetic "rest and recover" half underperforms. Over time, that imbalance shows up in the vascular system that supplies the penis.

Erections are vascular events. They require parasympathetic activation, smooth muscle relaxation in the cavernosal arteries, and adequate blood flow into the corpora cavernosa. When the autonomic nervous system is locked into a chronic sympathetic-dominant pattern, the parasympathetic signal that initiates erection gets drowned out.

Studies on combat veterans with PTSD have documented rates of erectile dysfunction that run two to three times the civilian baseline after adjusting for age, BMI, and cardiovascular risk factors. The mechanism is consistent with what cardiologists and urologists already know about ED being an early marker of vascular and autonomic problems.

Cohen and colleagues, among others, have published on the relationship between PTSD-induced autonomic changes and sexual dysfunction. The chain runs from chronic hyperarousal to endothelial dysfunction to impaired nitric oxide signaling to vascular ED. It's a slow, accumulating mechanism, which is part of why ED tends to show up years after the PTSD diagnosis rather than immediately.

I want to be careful with this. The fact that two conditions co-occur at elevated rates doesn't prove causation in any individual case. What the literature establishes is medical plausibility, which is what 38 CFR § 3.310 actually requires. A nexus letter has to show the proposition is at least as likely as not, not prove that the specific veteran's ED was caused by their specific PTSD.

Pathway Two: SSRIs, SNRIs, and Benzos Cause ED Directly

This is the cleaner of the two pathways from a documentation standpoint, and the one that, in my reading of the BVA decisions, wins more cleanly when it's argued well.

Most veterans with a PTSD diagnosis end up on at least one of the following: SSRIs like sertraline (Zoloft), paroxetine (Paxil), or fluoxetine (Prozac); SNRIs like venlafaxine (Effexor) or duloxetine (Cymbalta); benzodiazepines like clonazepam (Klonopin) or alprazolam (Xanax); or sleep agents like trazodone or mirtazapine.

Sexual dysfunction is a well-documented side effect across all of these classes. The FDA-approved prescribing information for every SSRI lists it as an adverse reaction. Published rates vary, but somewhere between 30% and 70% of men on SSRIs experience some form of sexual dysfunction, including reduced libido, delayed or absent ejaculation, and erectile dysfunction.

The mechanism is reasonably well understood. SSRIs increase serotonergic tone, which inhibits sexual function through multiple receptor subtypes. SNRIs add noradrenergic effects on top. Benzodiazepines and other sedatives work through GABAergic pathways that further dampen arousal.

For VA purposes, this is the cleanest version of a secondary chain. PTSD is service-connected. The medication treating PTSD causes ED as a documented side effect. The ED is, under 38 CFR § 3.310, "proximately due to" the service-connected condition through the intermediate step of treatment. The Federal Circuit and CAVC have both held that intermediate causal steps don't break the chain.

The strongest nexus opinions I've seen in this area do three things. They identify the specific medications the veteran is on. They cite the prescribing information or relevant medical literature on sexual dysfunction as a documented side effect. And they explain that even if the underlying PTSD didn't directly cause the ED, the medications required to treat the PTSD did.

That third move, in particular, defeats a lot of C&P denials that try to attribute the ED to age, cardiovascular factors, or "unknown etiology." If the veteran started having ED after starting SSRIs, the temporal sequence does a lot of the work on its own.

DC 7522 and the 2021 Rule Change Most Veterans Missed

Erectile dysfunction has its own diagnostic code at 38 CFR § 4.115b, DC 7522. The November 2021 amendment changed the rating structure in a way that I don't think most veterans have caught up to.

Under the pre-2021 version of DC 7522, ED was rated at 0% unless the veteran had "physical deformity of the penis with loss of erectile power." If both were present, the rating was 20%. "Physical deformity" was interpreted narrowly, and most veterans with garden-variety ED had no visible deformity to point to. Almost every ED rating came out at 0% schedular.

The November 2021 amendment kept the 20% maximum but clarified what counts as "deformity." The amended rule recognizes that conditions like Peyronie's disease, post-surgical changes, scarring, and other documented anatomical abnormalities can qualify. The amendment also clarified that the deformity and the loss of erectile power don't have to be from the same underlying cause. A veteran with Peyronie's disease plus medication-induced ED can potentially qualify for the 20% rating even though the deformity and the dysfunction have different proximate causes.

The 20% rating is the only schedular money in this picture. Without documented deformity, the rating sits at 0%, and the only compensation flowing is SMC-K at $139.87 per month. With documented deformity plus loss of erectile power, the schedular rating is 20%, and SMC-K still pays on top.

The 20% deformity tier is still rare. Most veterans with ED secondary to PTSD don't have penile deformity, and the November 2021 amendment didn't open the floodgates. It made the 20% tier modestly more accessible than before. If your case fits, it's worth knowing about. Otherwise, the SMC-K trigger is where the money lives.

The SMC-K Trigger: Why the 0% Rating Is Misleading

This section matters more than any other. When a veteran gets service connection for ED at 0% under DC 7522, that grant is supposed to automatically trigger an SMC-K award under 38 CFR § 3.350(a). The 0% rating and the SMC-K award are two separate things, governed by two different parts of the regulation, and the automatic trigger gets missed by raters constantly.

I wrote a full post on this a few weeks back, but the short version applies just as cleanly to ED secondary to PTSD as it does to direct service connection.

How § 3.350(a) defines "creative organ"

Here's the logic. 38 CFR § 3.350(a) provides for Special Monthly Compensation for "anatomical loss or loss of use of one or more creative organs." A "creative organ" means a reproductive organ. The penis qualifies. The regulation explicitly recognizes "loss of use" as a triggering condition. VA jurisprudence has consistently held that loss of erectile power is loss of use of the penis for SMC-K purposes.

What the Board says about the automatic trigger

When a veteran is granted service connection for ED, regardless of the schedular rating, the rater is supposed to simultaneously award SMC-K. This applies whether the ED grant is direct, secondary to PTSD, secondary to diabetes, secondary to medications, or anything else. The SMC-K trigger flows from the ED grant itself.

The Board has been crystal clear on this. From BVA decision A25025047, which I quoted at length in my SMC-K post:

"The Veteran should have been automatically granted SMC for loss of use of creative organ. VA's failure to do this constitutes clear and unmistakable error."

The word "automatic" is the Board's, not mine. The regulation imposes an affirmative duty on the rater to evaluate SMC entitlement on their own initiative.

In practice, this fails all the time. The pattern in the BVA decisions I've analyzed runs like this. The rater grants ED secondary to PTSD at 0%. The decision says "service connection for erectile dysfunction is granted, evaluated as 0% disabling" and says nothing about SMC-K. The veteran reads "0%" and concludes they got nothing. They file the letter and move on. The missing $139.87 a month never gets noticed.

If you have a service-connected ED rating and your monthly VA payment doesn't include an additional $139.87 (or $1,678.44 per year), you may have a missed SMC-K award.

The Retroactive Math When SMC-K Gets Missed

If the SMC-K trigger was missed at the original ED grant, the path to recover is Clear and Unmistakable Error under 38 CFR § 3.105. I covered the full CUE framework in the SMC-K post, so I'll keep this short.

Three features of CUE make it the right vehicle for missed SMC-K. CUE has no time limit, so a 20- or 30-year-old rating decision is still in play. CUE awards are retroactive to the original effective date that should have been assigned. And the "undebatable" pleading standard, which is a high bar in most contexts, is usually met cleanly for missed automatic SMC-K because the regulation is explicit and the failure to apply it is textbook CUE.

The retroactive math depends on how far back the ED service connection effective date goes. Rough estimates using historical SMC-K rates (which have ratcheted up with COLA every year):

A veteran with an ED effective date in 2003 correcting in 2026 recovers roughly 23 years of missed payments. Using a blended average over that period (from around $90/month in 2003 to $139.87/month in 2026), the retroactive award works out to roughly $27,000 to $30,000, tax-free.

A veteran with a 2015 effective date is looking at about 11 years, or roughly $15,000 to $17,000 tax-free.

A veteran with a 2020 effective date is at about 6 years, or roughly $8,500 to $9,500 tax-free.

These are rough numbers, not promises. Actual awards depend on precise effective dates and historical rate tables. The order of magnitude is the point. For any veteran whose ED service connection is more than a few years old and whose monthly payment doesn't include SMC-K, the retroactive exposure is real money.

Documentation That Tends to Hold Up at the Board

I want to be observation-oriented here rather than prescriptive. The BVA cases I've analyzed that ended in grants for ED secondary to PTSD tend to share a few documentation features. The ones that ended in denials tend to be missing those features.

The medication list. When a claim file includes a clear chronological record of PTSD medications and when they were prescribed, the SSRI / SNRI / benzo pathway becomes much easier for the Board to follow. A VA pharmacy printout or a list from the treating provider both tend to work. Fragmentary medication histories are harder for the Board to evaluate.

A urology consult or evaluation. The Board cares about whether the veteran has actually been evaluated for ED rather than just self-reporting symptoms. A urology consult, a documented diagnosis, and ideally a sexual function inventory all show up in the records of cases that grant. The diagnosis can come from primary care or mental health, but a urology consult tends to make the record cleaner.

A statement that connects the chain. The strongest cases tend to have a medical opinion that names the chain explicitly, from PTSD diagnosis to medication regimen to documented ED. Some of the cleanest opinions I've seen are from the treating psychiatrist or primary care provider, written as a letter that explains the temporal sequence and references the prescribing information.

I'm not going to tell anyone what to put in a nexus letter, that's not my role. The pattern in granted cases is consistent though. The opinions that win identify a specific pathway, cite the medication or autonomic mechanism, and tie the chain to the individual veteran's documented history.

Common Pitfalls I See in the BVA Record

A few patterns show up over and over in the cases that get denied or stuck in remand.

Filing under DC 7522 without claiming SMC-K. The most common one. The veteran files for ED secondary to PTSD, gets a 0% schedular rating, and the rater says nothing about SMC-K. The veteran accepts the 0% and moves on. The automatic SMC-K trigger goes unaddressed, and the $139.87/month never starts flowing.

Missing the post-2021 penile deformity tier. For veterans with actual anatomical changes (Peyronie's, post-surgical scarring, traumatic injury), the November 2021 amendment opened a path to a 20% schedular rating that wasn't really viable under the old rule. Veterans with original 0% ratings assigned before the rule change may have an opportunity to file for an increased rating under the amended DC 7522.

Bare-bones C&P opinions that hang the case on age or cardiovascular factors. C&P examiners often attribute ED to "age and cardiovascular risk factors" without engaging with the medication chain or the autonomic mechanism. The Board has noted that those opinions don't address the legally relevant question under 38 CFR § 3.310, which is whether PTSD or its treatment proximately caused or aggravated the ED.

The aggravation theory getting dropped on appeal. Some appeals focus exclusively on causation and skip aggravation entirely. Even when the causation case is weak, an aggravation argument can carry the claim, particularly when the veteran had some baseline erectile difficulty that got measurably worse after PTSD treatment started.

C&P exam adequacy issues. From my broader ED research, 51% of C&P exams for ED were found inadequate by the Board, with 114 cases remanded specifically for inadequate exams. A lot of those remands involve the examiner failing to address the secondary connection to PTSD or to the medication regimen.

The Combined Rating Picture

The schedular math on ED secondary to PTSD is usually clean. Most ED ratings come out at 0% and don't move the combined rating at all. The SMC-K award is paid in addition to base compensation rather than being folded into the combined rating calculation.

For a veteran rated at 70% PTSD in 2026, the base monthly rate is roughly $1,756 (single veteran, no dependents). If ED secondary to PTSD is granted at 0% plus SMC-K, the combined rating stays at 70%, and the veteran adds $139.87/month. Total compensation goes from $1,756 to roughly $1,896.

If the veteran qualifies for the 20% schedular tier under the amended DC 7522, the combined math runs: 70% PTSD as the larger rating, leaving 30% remaining capacity. The 20% ED rating takes 20% of that 30%, which is 6%. 70 plus 6 is 76, which rounds to 80%. Combined rating goes from 70% to 80%, and SMC-K still pays on top.

For a veteran at 70% PTSD moving to 80% combined plus SMC-K, monthly compensation goes from $1,756 to roughly $2,059 plus $139.87 SMC-K, for a total of about $2,199. That's a delta of about $443/month, or $5,316/year, tax-free.

For most veterans, the 0% plus SMC-K combination is the more likely outcome. The monthly headline number isn't huge. The cumulative dollars over a decade plus the retroactive exposure on a missed award is where the math gets meaningful.

Bottom Line

ED secondary to PTSD is one of the most under-paid corners of the VA system. The medical pathways are well-established: autonomic dysregulation causing vascular ED, and SSRI / SNRI / benzodiazepine medications causing pharmacological ED. 38 CFR § 3.310 combined with Allen v. Brown's recognition of aggravation theory gives veterans two independent ways to win. The 0% schedular rating under DC 7522 is supposed to automatically trigger an SMC-K award worth $139.87/month, tax-free, for life. The November 2021 amendment to DC 7522 created a 20% compensable tier for veterans with documented penile deformity. The single most common error in the BVA record is veterans accepting a 0% rating without realizing SMC-K should have been awarded simultaneously. For older missed awards, CUE under 38 CFR § 3.105 has no time limit and pays back to the original effective date, which can mean five-figure retroactive recoveries. The published SMC-K post on the Claim Raven blog covers the CUE pathway in detail.

Methodology and Limitations

  • Data source: Claim Raven's analysis of 783 BVA decisions involving erectile dysfunction claims, including the subset granted as secondary to PTSD. Medical literature references drawn from published research on PTSD, autonomic dysfunction, and psychiatric medication side effects.
  • Sample size: 783 ED appeals total at the BVA level (61 granted, 663 denied, 57 remanded). Secondary-to-PTSD subset counts aren't separately tabulated in the current aggregates. * Classification approach: Cases categorized by primary service-connected condition, theory of secondary connection (causation vs. aggravation), schedular rating awarded, and whether SMC-K was granted in the same decision or had to be added later.
  • Limitations:
  • These are cases that made it to the Board. They don't represent all ED secondary claims, including the ones granted cleanly at the RO level with both DC 7522 and SMC-K awarded simultaneously.
  • Medical literature citations are general references to research areas. Individual studies vary in methodology, sample, and effect size.
  • The retroactive math estimates use approximate blended historical SMC-K rates. Actual back-pay calculations require precise effective dates and the official rate tables in effect for each year.
  • The November 2021 amendment to DC 7522 is recent enough that the Board case law interpreting the amended language is still developing. The 20% deformity tier may evolve as more decisions are issued.
  • The "automatic" framing for SMC-K comes from BVA decision language quoting the regulatory standard. Individual rater behavior varies, and some RO decisions have correctly awarded SMC-K at the time of the original ED grant.
  • Combined rating examples assume single veteran, no dependents, at 2026 rates. Different family status and rating combinations produce different combined outcomes.

Disclaimer

This post is educational intelligence, not legal advice. Per 38 CFR § 14.629, only VA-accredited representatives (VSOs, claims agents, or attorneys) may provide personalized guidance on specific claims. The patterns described in this post are drawn from Claim Raven's analysis of 783 Board of Veterans' Appeals decisions involving erectile dysfunction claims. For guidance on your specific situation, contact an accredited VSO, claims agent, or attorney. Find accredited representatives at VA.gov.

Where to go next

-Landon Founder, Claim Raven | U.S. Army Veteran